CJC-1295

evidence score

peptide

Gray Market

106 studies

Modified GRF 1-29Mod GRF 1-29CJC1295+1 more

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Two forms exist: with DAC (Drug Affinity Complex) extending half-life to 6–8 days via albumin binding, and without DAC (Modified GRF 1-29) with a 30-minute half-life mimicking natural pulsatile GH release. Used to stimulate GH and IGF-1 for muscle growth, fat loss, recovery, and anti-aging. Commonly combined with ipamorelin for synergistic GH pulse amplification.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

No formal trials

Research Sync

Feb 19, 2026

Dosing

Typical

200 mcg

100 mcgRange300 mcg

Frequency1–3x/day without DAC; 1–2x/week with DAC

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~30 min without DAC; 6–8 days with DAC

Onset15–30 minutes post-injection (GH pulse)

DurationGH pulse 2–3 hours; IGF-1 elevation sustained with DAC

Routes

subcutaneous

intramuscular

Evidence Score

Level B — Moderate

106 studies indexed

Scoring Factors

Volume(40%)~41/100

Quality(30%)~40/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

CJC-1295 is currently categorized as a peptide compound.

Evidence is moderate (65/100): promising signal from 106 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

GHRH receptor agonist on pituitary somatotrophs; stimulates pulsatile GH release and downstream IGF-1 production

Practical Context

Strongest current signals

Level C: This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Level C: The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.
Level C: Growth hormone-releasing hormone and its analogues in health and disease.